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Abstract
Introduction: Tobacco smoke is known to be the main cause of lung, head and neck tumors. Recently, evidence
for an increasing breast cancer risk associated with tobacco smoke exposure has been emerging. We and other
groups have shown that nicotine, as a non-conventional carcinogen, has the potential to facilitate cancer genesis
and progression. However, the underlying mechanisms by which the smoke affects the breast, rather than the
lung, remain unclear. Here, we examine possible downstream signaling pathways of the nicotinic acetylcholine
receptor (nAChR) and their role in breast cancer promotion.
Methods: Using human benign MCF10A and malignant MDA-MB-231 breast cells and specific inhibitors of
possible downstream kinases, we identified nAChR effectors that were activated by treatment with nicotine. We
further tested the effects of these effector pathways on the regulation of E2F1 activation, cell cycle progression and
on Bcl-2 expression and long-term cell survival.
Results: In this study, we demonstrated a novel signaling mechanism by which nicotine exposure activated Src to
sensitize epidermal growth factor receptor (EGFR)-mediated pathways for breast cancer cell growth promotion.
After the ligation of nAChR with nicotine, EGFR was shown to be activated and then internalized in both MCF10A
and MDA-MB-231 breast cancer cells. Subsequently, Src, Akt and ERK1/2 were phosphorylated at different time
points following nicotine treatment. We further demonstrated that through Src, the ligation of nicotine with nAChR
stimulated the EGFR/ERK1/2 pathway for the activation of E2F1 and further cell progression. Our data also showed
that Akt functioned directly downstream of Src and was responsible for the increase of Bcl-2 expression and long-
term cell survival.
Conclusions: Our study reveals the existence of a potential, regulatory network governed by the interaction of
nicotine and nAChR that integrates the conventional, mitogenic Src and EGFR signals for breast cancer
development.
Introduction
Tobacco smoke is strongly linked to the onset of various
types of human malignancies. According to epidemiolo-
gical studies, about 30% of cancer deaths every year in
the United States are associated with exposure to
tobacco smoke or tobacco products, indicating the
importance and urgency for cessation of active and pas-
sive cigarette smoke [1,2]. Tobacco smoke is known to
be the main cause of lung, head and neck tumors
[1,3-5]. Recently, evidence has been emerging for the
increasing breast cancer risk associated with tobacco
smoke exposure [6-9]. Nicotine, one of the important
constituents of tobacco interacts with nicotine acetyl-
choline receptors (nAChR) and functions in either the
motor endplate of muscle or at the central nervous sys-
tem for the establishment of tobacco addiction [10-13].
Studies also showed that nAChR is expressed in various
non-neuronal cells and the ligation of the receptor acti-
vates various intracellular signaling pathways in these
cells, suggesting that nicotine has the potential to regu-
late cell proliferation [14-16]. It was reported that nico-
tine potently induced secretion of different types of
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cleavage of various substrates in the extracellular matrix
to facilitate metastasis and tumor progression [5]. In
mammary epithelial or tumor cells, the exposure of
nicotine initiated a signaling cascade that involved PKC
(protein kinase C) and cdc42, and consequently acceler-
ated cell migration [7]. Furthermore, the anti-apoptotic
property of nicotine in breast cancer cells has been
demonstrated to be through upregulation of Bcl-2 family
members [8]. The addition of nicotine desensitized
MCF7 cells to doxorubicin-mediated cyctoxicity [17].
All these data indicate that nicotine plays a positive role
in the regulation of cell growth and survival. However,
the underlying mechanisms of nicotine in facilitating
mitogenic activities remain unclear.
nAChR consists of nine a-subunits (a2 to 10) and two
b-subunits (b2 and 4) [10-13]. The subunits of nAChR
form heteromeric or homoeric channels in different
combinations in neuronal cells, which are highly Ca
++
permeable to allow the penetration of Ca
++ flux [10-13].
Upon the engagement with nAChR in non-neuronal
cells, nicotine activates calmodulin-dependent protein
kinase II, PKC, phosphodylinositol-3-kinase (PI3K)/Akt
and Rac family that are often involved in the regulation
of cell growth, adhesion or migration [7,18-20]. The
activation of nicotine receptors was also shown to trig-
ger Ras/Raf/MEK/ERK–Ras/Raf/MEK (mitogen-activated
protein kinase)/ERK (extracellular-signal-reguated
kinase)– signaling [7,21,22]. In addition, the involvement
of nicotine in the activation of the tyrosine kinase JAK-2
(Janus Kinase-2) and transcription factor STAT-3 (Sig-
nal Transducer and Activator of Transcription-3) in oral
keratinocytes was also observed [22].
The epidermal growth factor receptor (EGFR) is a
transmembrane protein receptor that possesses an
intrinsic tyrosine kinase activity [23,24]. The EGFR
family consists of several members, including EGFR,
ERBB2/HER2/NEU, ERBB3 and ERBB4. The ligation of
EFGR activates mitogenic-related signaling pathways,
leading to various cellular responses. An increased
level of mutation of EGFR has been detected in many
human tumors, including breast cancer, which were
often accompanied with a poor prognosis [25,26].
Upon growth factor stimulation, EGFR undergoes con-
formational changes and being phosphorylated, fol-
lowed by being internalizated [24-26]. EGFR signaling
subsequently mobilizes multiple signaling cascades,
including MAPK (microtubule-associated protein
kinase), PI3K (phosphodylinositol-3-kinase) and STAT
(signal transducer and activator of transcription) path-
ways. However, a specific biological outcome, following
EGFR activation, is determined by cross-talk or coop-
eration of its downstream effectors and parallel
pathways.
As with EGFR, nAChR subunits appear to be activated
through tyrosine phospohrylation [18,27]. Using Xeno-
pus oocytes, neuroblastoma or other types of cells, it
was shown that the a7 subunit of nAChRs was regu-
lated by tyrosine phosphorylation and Src family kinases
[18]. The treatment of colon cancer cells with nicotine
activated c-Src as well as augmented EGFR expression
[28]. Furthermore, in the colon cancer xenograft model,
inhibitors of EGFR and Src dramatically blocked the
tumor formation promoted by nicotine injection [29].
All studies suggest the existence of cooperation between
nAChR and EGFR.
During the process of tumor initiation and progres-
sion, aberrant growth signaling plays an important role
in the perturbation of growth restriction and cell cycle
checkpoints. Numerous factors play a role in the regula-
tion of this process, which includes growth factors,
kinases, phosphatases as well as extracellular matrix
components. Growth receptors, when interacting with
corresponding ligands, initiate the process of cell cycle
progression and migration in cells. In order to success-
f u l l yt r a n s m i ts i g n a l i n gf r o mt h em e m b r a n et ot h e
nucleus, receptors appear to communicate with each
other to modulate the magnitude of signaling cascades
and further activate transcription factors for the promo-
tion of various biological processes. Nicotine has been
demonstrated to induce nAChR phosphorylation, which
further stimulated the dissociation of E2F1 from Rb and
subsequent binding to cdc6 and cdc25A promoters for
cell cycle progression in lung cancer cells [18]. These
events which are induced by nicotine are most likely
responsible for the increase of breast cancer risk by
active or passive tobacco smoking.
In this study, we demonstrate a novel signaling
mechanism whereby nAChR promotes breast cell
growth through the sensitization of EGFR-mediated sig-
naling. Upon nicotine-induced EGFR activation, Src, Akt
and ERK1/2 were phosphorylated in MCF10 and MDA-
MB-231 breast cancer cells, leading to the upregulation
of E2F-1, Bcl-2 expression, and long-term cell survival.
In this process, Src functioned directly downstream of
nAChR to activate EGFR/ERK1/2 as well as Akt path-
ways, respectively. The identification of the cross-talk
between nicotine and EGFR connected through Src pro-
vides a new insight into the potential carcinogenic effect
of tobacco smoke on the breast.
Materials and methods
Cells, reagents and infection procedure
Human benign MCF10A and malignant MDA-MB-231
breast cancer cells were purchased from ATCC (Mana-
ssas, VA, USA). MCF10A cells were cultured in
DMEM/F12 medium supplemented with 5% donor
horse serum and antibiotics without growth factors.
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Page 2 of 11MDA-MB-231 cells were maintained in Dulbecco’s
Modified Eagle’s Medium (DMEM) with 10% fetal calf
serum, 4 mM L-glutamine and antibiotics. dn-Src or dn-
Akt (dominant-negative Src or Akt) was inserted into
MSCV (murine stem cell virus) retroviral vector and
subsequently transiently infected into the cells.
Nicotine and the nAChR inhibitor mecamylamine
hydrochloride (MCA) were purchased from Sigma-
Aldrich, Inc. (St. Louis, MO, USA). The Akt inhibitor
KP372-1 and the ERK inhibitor PD98059 were obtained
from EMD Chemicals Inc. (San Diego, CA, USA). The
antibodies were purchased from BD Parmingen (La
Jolla, CA, USA).
The procedure for the infection with genes inserted in
the MSCV retroviral vector was detailed in the User
Manual provided by the company (BD Biosciences Clon-
tech, Heidelberg, Germany). Briefly, after co-transfected
expression vector, Gag and Env constructs, PT67 cells
were grown for 48 hours. Subsequently, the medium
was collected for the infection.
The experiments performed in this study do not
require Institute Ethics Board approval, because only
commercially available cell lines were used.
Immunoblotting
Following treatment, cell lysates were prepared and pro-
teins were separated by SDS-PAGE gels. Membranes
were incubated with the designated primary antibody
(1:1000 for all antibodies) overnight in a cold-room at 4°
C. Bound primary antibodies were reacted with corre-
sponding second antibodies for 2 hours and detected by
chemiluminescence. The anti-phosphor-EGFR (tyr-
1068), EGFR, phosphor-E2F, E2F, phosphor-Src, Src and
Bcl-2 antibodies were purchased from Santa Cruz, Inc.
The anti-phosphor-PDGFRb, PDGFRb, phosphor-ERK1/
2, ERK1/2, phosphor-Akt and Akt antibodies were from
Cell Signaling Technology, Inc, Donvers, MA, USA
GST/Grb2 pull-down assay
GST/Grb2 fusion protein was purchased from Invitro-
gen. After treatments, cell lysates were incubated with
the fusion protein (1 μg) immobilized on glutathione-
sepharose beads as indicated in the protocol provided
by the company. Bound proteins were washed and sub-
jected to SDS-PAGE.
ChIP assay
After treatments, cells were cross-linked with 1% formalde-
hyde for 15 minutes at room temperature. The cross-link-
ing was stopped by the addition of glycine. Cells were
harvested and sonicated. Lysates were immunoprecipitated
with the corresponding antibodies. The different bindings
o fE 2 F 1 ,R bt oc d c 2 5 Aw e r ea n a l y z e db yP C R .T h e
sequences of the primers used are: cdc25A promoter size
of 209 bp (5’-tctgctgggagttttcattgacctc and 3’-ttggcgccaaacg-
gaatccaccaatc); c-Fos promoter size of 209 bp (5’-
tgttggctgcagcccgcgagcagttc and 3’-ggcgcgtgtcctaatctcgtgag-
cat) [18]. PCR products were resolved on a gel.
[
3H]thymidine incorporation
Cells were grown in Petri dishes until 60% to 70% con-
fluence and five wells were for the control and each
treatment. The cells were cultured in medium contain-
ing 0.5% serum for 24 hours. Subsequently, the cells
were grown in fresh medium containing 0.5% of serum
plus 4 μCi/ml of [
3H]thymidine (Perkin Elmer Life
Sciences, Waltham, MA, USA) with or without various
treatments. The cells were labeled for 8 hours at 37°C.
After precipitation with cold 10% trichloroacetic acid,
the cells were dissolved in 0.5 ml of 0.1 M NaOH over-
night at 4°C. The amount of radioactivity in each sample
was counted using a scintillation machine.
Cell proliferation assay
Cells (2 × 10
5) were plated in 12-well plates and cul-
tured in medium containing 0.5% serum, which is desig-
nated as day 1. Subsequently, the cells with or without
nicotine treatment were grown for another three days.
The numbers of viable cells were determined by trypan
blue staining and counted daily using a hemocytometer.
Colony formation assay
Cells (250 cells/plate) were seeded in 100 mm-Petri
dishes and cultured in growth medium containing nico-
tine alone or nicotine plus other inhibitors for ten days.
The medium with nicotine or its combination with
other inhibitors was changed every four days. After
staining, the numbers of colony were counted.
Statistical analysis
Three to five independent repeats were conducted in all
experiments. Error bars represent these repeats. A Stu-
dent’sTt e s tw a su s e da n daP value of < 0.05 was con-
sidered significant.
Results
EGFR was activated and internalized in breast cancer cells
following treatment with nicotine
Upregulation of EGFR signaling plays an important role
in breast cancer development and cooperation between
nAChR and EGFR has been suggested in cancer progres-
sion [29,30]. However, the mechanisms by which cigar-
ette smoke or nicotine exposure promotes breast
tumorigenesis remain unclear. This study aimed at inves-
tigating the existence of a cross-talk between nAChR and
EGFR for the promotion of breast cancer growth. After
treatment with nicotine at different time points, a cell
lysate (without the nucleus) was prepared from human
Nishioka et al. Breast Cancer Research 2011, 13:R113
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expression of EGFR was then tested by immunoblotting
(Figure 1A). The levels of EGFR in the lysate from cells
treated with nicotine for 30 minutes or 1 hour were simi-
lar to those in untreated cells. Interestingly, EGFR (>
85%) became undetectable in the lysate extracted from
MCF10A cells treated with nicotine for 2 hours. In the
presence of MCA (a nAChR inhibitor), the level of EGFR
in the same cells subjected to the same treatment did not
decline (Figure 1B). It appears that the disappearance of
EGFR was specifically triggered by nicotine treatment.
Upon motigenic activation, EGFR is often seen to be
phosphorylated at its tyrosine residues and then being ter-
minated [23]. Since EGFR in the cells became undetectable
2 hours after nicotine exposure, the phosphorylation status
of the receptor at an earlier time point (1 hour) in the
treatment was examined (Figure 1C). The lysates from
untreated or treated cells were immunoprecipitated with
an anti-EGFR antibody and then subjected to immuno-
blotting, using the anti-phosphor-tyrosine antibody (Figure
1C). The phosphorylated EGFR in MCF10A cells was
recognized by the antibody 1 hour after the treatment,
which was abrogated by the addition of either MCA or
AG1478 (an EGFR inhibitor). For confirmation purposes,
the phosphor-(Tyr1068)-EGFR antibody was also used to
detect EGFR phosphorylation status and a similar result as
that shown in Figure 1C was obtained (Figure 1D). It is
known that through association with Grb2, active EGFR
triggers a cascade of its downstream effectors [31]. To test
whether nicotine-activated EGFR was able to bind to
Grb2, MCF10A cells were treated with nicotine or EGFR
and immunoprecipitation was then performed (Figure 1E).
The receptor was found to be bound to a GST (glu-
tathione-S-transferase)/Grb2 fusion protein in either nico-
tine- or EGF-treated cells, but not in untreated control
cells. The data further suggested that the ligation of nico-
tine with nAChR stimulated EGFR.
EGFR in breast cancer cells is specifically activated by
nicotine ligation
To test if nAChR activation might globally sensitize cell
surface receptors, MCF10A cells were treated with
0             30’        1 h           2 h 
MCF10A 
EGFR 
actin 
0             30’        1 h          2 h  nicotine 
MDA-MB-231  A 
EGFR 
0                   1 h                 2 h  nicotine 
actin 
-             +             +  MCA 
MCF10A  B 
-                +  EGF (0.5 PM, 30’)  nicotien (0.5 PM, 1h) 
EGFR 
Grb2 
E 
-              + 
EGFR 
Grb2 
-          +         +         + 
-          -          +         - 
-          -          -          + 
nicotine (1h) 
MCA 
AG1478 
D  MCF10A 
actin 
p-EGFR (tyr-1068) p-EGFR 
-          +        +         + 
-          -         +         - 
-          -         -         + 
nicotine (1h) 
MCA 
AG1478 
C  MCF10A 
EGFR 
Figure 1 Activation of EGFR in human breast cancer cells after nicotine treatment.( A) Human MCF10A and MDA-MB-231 cells were
treated with nicotine (0.5 μM) for various times and cell lysates (without nucleus) were extracted for testing EGFR expression by immunoblot.
The blot was re-probed with an anti-b-actin Ab for loading control. (B) Expression of EFGR in nicotine-treated MCF10A cells in the presence of
MCA (50 nM) was analyzed by immunoblot. The blot was re-probed with an anti-b-actin antibody for loading control. (C and D) MCF10A cells
were treated with MCA (50 nM) or AG1478 (100 nM) for 15 minutes prior to 1 hour of nicotine exposure. The phospohrylation pattern of EGFR
in nicotine-treated MCF10A cells was examined by immunoprecipitation with anti-EGFR antibody and immunoblotting with the anti-phosphor-
tyrosine antibody, or immunoblotting with the anti-phosphor (Tyr 1068) antibody. The blot was re-probed with an anti-EGFR antibody for
loading control.(E) With or without treatment with nicotine (left panels) or EGF (right panels), the cell lysates were extracted and precipitated
with glutathione S-transferase/growth factor receptor-bound protein 2 (GST/Grb2) fusion protein. Subsequently, the precipitates were subjected
to immunoblotting. The blot was also re-probed with anti-Grb2 antibody for the control.
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using anti-platelet growth factor b subunit (PDGFRb)
antibody (Figure 2A). Unlike EGFR, the level of PDGFR
in nicotine-treated cells was unchanged. To further test
the activation status of PDGFR, MCF10A cells were
treated with PDGF for 30 minutes or nicotine for 1
hour and immunoblotting was performed using the
anti-phosphor-PDGFRb antibody (Figure 2B). The
receptor was phosphorylated after treatment with
PDGF, as expected. However, the phosphor-PDGFRb
was unable to be visualized by the antibody in nicotine-
treated cells. These data suggested that the sensitization
or internalization of EGFR in breast cancer cells is spe-
cifically induced by nicotine exposure.
Downstream effector kinases were activated after
nicotine treatment
It is known that tyrosine kinase Src is not only down-
stream of EGFR but also of nAChR [29,30]. Thus, the
activation status of Src in MCF10A cells was examined
after nicotine treatment at different time points (Figure
3A, upper two lanes). Src was not activated in untreated
cells. However, this kinase was phosphorylated 1 hour
after nicotine exposure and an increased amount of the
active form of this kinase was present in the cells 2
hours following treatment.
Akt and ERK1/2 often exert as receptor downstream
effectors of EGFR or Scr in mitogen-induced responses.
The phosphorylation status of these kinases was also
examined after MCF10A cells were treated with nicotine.
Two hours after nicotine treatment, the phosphorylated
f o r m so fE R K 1a n d2w e r ed e t e c t e db yt h ea n t i b o d yi n
the cells (Figure 3A, middle two lanes). Also, a high level
of phospohrylated Akt was detected by the antibody 1
hour after nicotine exposure and a smaller amount of the
phosphorylated protein was seen at 2 hours of the treat-
ment (Figure 3A, bottom two lanes). The same activation
patterns of these kinases were seen in nicotine-treated
MDA-MB-231 cells (data not shown). In comparison, a
fast activation pattern of these kinases was seen in
response to EGFR treatment in the cells. Following the
treatment with EGF for 10 or 15 minutes, Src, ERK1/2 or
Akt was phosphorylated (Figure 3B). One hour after the
treatment, these kinases were no longer active (data not
shown). Since these kinases activated with different acti-
vation kinetics upon nicotine treatment, the results indi-
cated that distinct mechanisms are involved in the
regulation of these nAChR downstream effectors.
nAChR, via Src, activates EGFR-dependent or
-independent downstream pathways following nicotine
treatment
Since c-Src, Akt, and ERK1/2 in the cells were activated
after nicotine treatment, it was possible that these
kinases were subjected to different regulations. To test
this, we treated MCF10A cells with MCA (a nAChR
inhibitor), and then with nicotine for various time points
(Figure 4A). Neither ERK1/2 nor Akt was phosphory-
lated in nicotine-treated cells after the blockade of
nAChR. A dominant-negative src was then used to sup-
press Src. To verify if the dn-src had an inhibitory effect
on endogenous Src, we transiently transfected the con-
struct into MACF10A cells and treated the cells with
EGF (a known Src activator). Indeed, the introduction
of dn-src efficiently blocked EGF-induced Src phosphor-
ylation (more than 90%) (Figure 4B, left panels). After
dn-src was transiently transfected into the cells, the
phosphorylated form of ERK1/2 or Akt could not be
detected in nicotine-treated cells (Figure 4B, middle and
right panels). We then treated MCF10A cells with
AG1478 prior to nicotine exposure. The inhibition of
EGFR by the inhibitor prevented nicotine-mediated
phosphorylation of ERK1/2 (Figure 4C, upper panels),
but had no effect on nicotine-induced Akt activation.
Subsequently, the cells were exposed to PD168393 (an
ERK inhibitor) (Figure 4C, middle panels) or KP372-1
(an Akt inhibitor) (Figure 4C, bottom panels), prior to
the addition of nicotine. The inhibitors suppressed the
activation of the corresponding kinases, respectively.
T h ed a t as u g g e s t e dt h a tS r ci sd o w n s t r e a mo fn A C h R
and responsible for the sensitization of EGFR or Akt
pathway. However, ERK1/2 signaling appeared to be
controlled by EGFR in nicotine-mediated, growth-
related action.
-                 +  nicotine (0.5 P PM, 2 h) 
PDGFR 
actin 
A 
-                 +                - 
-                 -                +  nicotine (0.5 PM, 1h) 
PDGF (250 ng/ml, 30’)
p-PDGFR 
PDGFR 
B 
Figure 2 Activation status of PDGFR in MCF10A cells in
response to nicotine treatment.( A) After the treatment with
nicotine, the expression of PDGFR in MCF10A cells was analyzed by
immunoblotting. The blot was re-probed with an anti-b-actin
antibody for loading control. (B) Following the treatments, the
expression of the phosphor-PDGFR in MCF10A cells was assayed
and the blot was re-probed with an anti-b-actin antibody for
loading control.
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pathway
EGF/EGF-related signals are able to activate down-
stream pathways to inactivate Rb, leading to the release
of E2F from its sequestration and the entry of cells to S
phase of the cell cycle [32]. To test whether nicotine
treatment could affect E2F1 activity in breast cancer
cells, a ChIP assay was conducted to analyze the occu-
pancy of E2F1 on its responsive cdc25A promoter (Fig-
ure 5A, left panel). Stimulation with nicotine for 2
hours induced the association of E2F1 with cdc25A pro-
moter in MCF10A cells. The blockade of Src by dn-src
or suppression of EGFR signaling by AG1478 abolished
the binding of E2F1 to the promoter induced by nico-
tine. Consistently, the inhibition of Akt by KP372-1 did
not affect E2F1 association with the promoter in nico-
tine-treated cells and the addition of PD168393 comple-
tely interfered with the binding. The promoter of c-Fos
was used as the control in the ChIP assay and E2F1 did
not bind to this promoter in response to nicotine treat-
ment (data not shown). The activation of E2F was also
tested by immunoblotting using the anti-phosphor-E2F
antibody and results similar to those found in the ChIP
assay were obtained (Figure 5A, right panels). The
results supported the notion that E2F1 activity induced
by nicotine treatment was governed by nAChR/Src/
EGFR/ERK1/2 signaling and Akt appeared to play no
role in this nicotine-mediated, growth promotion.
Since E2F1 was activated by the EGFR/ERK1/2 path-
way in our experimental setting, the [
3H]thymidine
incorporation assay was used to determine the role of
this pathway in DNA uptake in nicotine-treated
MCF10A and MDA-MB-231 cells (Figure 5B). After
serum starvation for 48 hours, the cells were treated
with nicotine or co-treated with various inhibitors in the
presence of [
3H]thymidine. Rates of DNA synthesis were
then measured. Under serum depletion conditions, little
[
3H]thymidine incorporation was observed in the cells.
A moderate amount of [
3H]thymidine (about 5 to 6
fold) was incorporated in nicotine-treated cells under
serum-starvation conditions. However, the addition of
AG1478 or PD168393 blocked the nicotine-induced
[
3H]thymidine incorporation into the cell genomes. In
comparison, KP372-1 treatment had a minimal, negative
role in DNA synthesis promoted by nicotine. As
expected, co-treatment of PD168393 and KP372-1 com-
pletely suppressed the incorporation of [
3H]thymidine.
Next, the effect of Src or Akt on cell growth in
response to nicotine exposure was assayed by cell prolif-
eration analysis. After 24 hours of serum starvation,
MCF10A or MDA-MB231 cells in the medium contain-
ing 0.5% serum were treated with PD168393, KP372-1
or infected with dn-src, prior to nicotine exposure, and
the number of cells was then counted for four consecu-
tive days (Figure 5C). MCF10A or MDA-MB231 cells
did not grow under serum-depletion conditions. How-
ever, the numbers of the cells were increased at day 2
after the treatment. The addition of PD168393 signifi-
cantly prevented nicotine-mediated growth promotion.
In comparison, KP372-1 had no negative effect on nico-
tine-mediated growth promotion. Again, concurrent
treatment with KP372-1 and PD168393 completely
blocked the nicotine-mediated effect on the growth of
MCF10A and MDA-MB-231 cells. The data further
B 
p-Src 
Src 
ERK1/2 
p-Akt 
Akt 
p-ERK1/2
0             10’            15’           30’  EGF 
MCF10A 
p-Src 
Src 
MCF10A  A 
p-ERK1/2 
ERK1/2 
0                     30’                     2h 
p-Akt 
Akt 
nicotine 
Figure 3 Activation status of Src, ERK1/2 and Akt in MCF10A cells following nicotine exposure.( A) After nicotine treatment for different
time periods, the phospohrylation form of Src, ERK1/2 or Akt in MCF10A cells was analyzed by the corresponding antibodies, using immunoblot.
(B) The expression of the phosphorylated Src, ERK1/2 or Akt in EGF-treated cells.
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ERK1/2/E2F1 signaling to promote cell growth.
Akt was involved in the regulation of cell survival upon
nicotine treatment
Persistent nicotine exposure was shown to upregulate
Bcl-2, which enhances cell survival as well as resistance
of cancer cells to chemo-drugs [33-36]. To test how
nicotine-mediated effector pathways were involved in
the regulation of Bcl-2 or cell survival, MCF10 cells
were co-treated with various inhibitors and nicotine for
two days and the expression of Bcl-2 was assayed by
immunoblotting (Figure 6A). The level of Bcl-2 expres-
sion in the cells was increased (about 2 fold) after nico-
tine treatment, which was not affected by its co-
treatment with PD168393. Interestingly, this nicotine-
mediated upregulation of Bcl-2 expression in the cells
was blocked by co-treatment with KP372-1. A similar
result was obtained in MDA-MB231 cells (data not
shown).
To determine the effect of various nicotine-mediated
signaling pathways on long-term cell survival, a colony
formation assay was performed (Figure 6B). After being
seeded, MCF10A and MDA-MB-231 cells formed colo-
nies 12 days later, and the addition of nicotine stimu-
lated the ability of the cells to form colonies (about 2
fold). Treatment with PD168393 or KP372-1 alone had
no obvious effect on the formation of colonies of the
cells. The co-treatment of nicotine with KP372-1, but
not with PD168393 significantly reduced the numbers of
g,
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ERK1/2 
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Figure 4 The hierarchy order of nAChR downstream effectors in MCF10A cells. (A) After the suppression of nAChR by MCA, the
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Page 7 of 11the cells that formed colonies. Concurrent treatment
with PK372-1 and PD168393 completely blocked
MCF10A or MDA-MB-231 cells from generating colo-
n i e s ,w i t ho rw i t h o u tn i c o t i n ee x p o s u r e .O v e r a l l ,t h e
data indicated that Akt might be responsible for nico-
tine-promoted cell survival.
Discussion
Cigarette smoke contains a variety of genotoxic carci-
nogens, many of which are derivatives of nicotine that
are formed during the curing of tobacco [1-3]. The
direct link between cigarette smoke and the onset of
lung cancer has long been established. Although the
correlation of the smoke with other types of cancer, in
particular breast cancer, has been suggested by epide-
miological investigations, the underlying molecular
mechanisms by which cigarette smoke promotes breast
cancer genesis and progression remain unclear. It is
known that nAChR is widely expressed in neurons and
neuromuscular junctions, but is also present in various
non-neuronal organs, tissues or cells, such as epithelial
cells from different organs and endothelial cells. Liga-
tion of nAChR has been shown to facilitate cell growth
and promote pro-survival activities in lung cancer or
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Figure 5 Involvement of E2F1 in cell growth promotion by nicotine.( A) Left panel: ChIP analysis of nicotine-treated MCF10A cells in the
presence or absence of dn-src, PD168393, AG1478 or KP372-1. Sonicated, cross-linked chromatin was immunoprecipitated with an anti-E2F1
antibody, and the purified DNA was assayed by PCR with the primers for cdc25A promoter. Right panels: After the same treatments as described
above, cell lysates were prepared and subjected to immunoblotting with the anti-phosphor-E2F antibody. (B) After different treatments, [
3H]
thymidine incorporation in the cells was measured. (C) After being serum-starved for 24 hours, the cells were cultured in the medium containing
0.5% serum plus various inhibitors, and the numbers of viable cells were counted for 4 days. Error bars represent SD (standard deviation), n =5 .
Nishioka et al. Breast Cancer Research 2011, 13:R113
http://breast-cancer-research.com/content/13/6/R113
Page 8 of 11other types of malignant cells [4-6]. We previously
demonstrated that exposure to nicotine augmented the
migration or invasion ability of benign or malignant
breast cancer cell lines, in which PKC and cdc42
played a crucial role [7]. As the continuation of the
investigation of the role of nicotine exposure in breast
tumorigenesis, we found that the engagement of nico-
tine with nAChR sensitized EGFR signaling via Src,
resulting in the activation of ERK1/2 and upregulation
of E2F1 transcriptional activity. We also found that the
inhibition of nAChR or Src abrogated the promotion
of cell proliferation conferred by nicotine treatment.
Furthermore, in response to nicotine treatment, ERK1
and 2 functioned downstream of EGFR and the sup-
pression of these kinases prevented the nicotine-
mediated activation of E2F1 and DNA synthesis. We
also showed that Akt appeared to be directly activated
by Src in nicotine-governed action and responsible for
upregulated Bcl-2 expression and increase cell survival
activity. Collectively, these findings identified the novel
intracellular targets Src/Akt and EGFR/ERK1/2 that
are differentially affected by nicotine exposure to facili-
tate breast cancer progression.
S i n c et h e r ei sal a c ko fu n d e r s t a n d i n ga b o u tt h e
underlying molecular mechanisms by which tobacco
smoke promotes turmorigenesis in other organs of
human body, rather than in the lung, nicotine has
become a major object of investigation, because it exists
in high concentrations in the blood stream of first-,
heavy second-hand smokers and nicotine users [37-39].
Although nicotine is not a conventional carcinogen, this
tobacco smoke-related compound has been shown to
induce the secretion of growth factors (such as bFGF,
TGF-a, calpains, and VEGF), resulting in the activation
of Raf, Akt or PKC pathways for the growth promotion
of lung epithelial or cancer cells and upregulation of
Bcl-2 signaling that is responsible for the increase in the
resistance to anti-cancer therapies [35,36]. The binding
of nicotine to nAChR initiated the activation of Src tyr-
osine kinase that further mediated cell cycle progression
of non-small cell lung cancer (NSCLC) [18]. Our cur-
rent study demonstrated that exposure of human breast
benign or malignant cancer cells to nicotine induced the
phosphorylation of Src that augmented cell growth- and
survival-related signaling. As a substance, nicotine is
able to diffuse rapidly into various organs and tissues.
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Page 9 of 11Thus, it is conceivable that this major component of
tobacco smoke in the blood stream can efficiently reach
the breast and bind to nAChR on the surface of breast
epithelial or cancer cells, which provides a growth
advantage locally. Indeed, studies have demonstrated
that cancer patients who were smokers or nicotine users
were more resistant to chemotherapy and had increased
metastasis of breast cancer. Furthermore, nicotine was
also reported to augment the proliferation of cell lines
derived from gastric, colon, bladder or pancreatic
tumors [14-16]. Therefore, the interaction of nicotine
and nAChR is an un-neglected factor in the regulation
of the growth in different tissues or organs.
EGFR belongs to a family of the receptor tyrosine
kinases and functions as a mediator to transmit cell sig-
naling initiated by extracellular growth factors to the
nucleus. Overexpression of EGFR or other family mem-
bers is frequently found in human tumors of epithelial
origin. Targeting EGFR family members has been attrac-
tive for developing new therapeutics with promising
clinical results [23-26]. In our current investigation, we
demonstrated that EGFR was activated and subsequently
internalized in breast cancer cells in response to nico-
tine treatment, accompanied by the cascade of the phos-
phorylation of several intracellular effector kinases.
Among these kinases, Src acted as a key regulator to
link nAChR signaling to EGFR and ERK1/2. In nicotine-
treated neuroblastoma or Xenopus oocytes cells, the a7
subunit of nAChR has been shown to undergo tyrosine
phosphorylation and Src was responsible for the activa-
tion of this subunit of the receptor [18]. Using in vitro
and xenograft assays, it was also reported that the levels
of Src and EGFR in colon cancer cells were significantly
increased following nicotine exposure [18]. Our experi-
m e n t ss h o w e dt h a tS r cf u n c t i o n sa sak e yd o w n s t r e a m
effector of nAChR and links nicotine signals to EGFR
and ERK1/2 to promote transient cell growth activities.
By studying the mechanisms of nicotine-mediated
cell growth promotion, we revealed that a cross-talk
occurred specifically between two important cell sur-
face receptors: nAChR and EGFR. This is the first
demonstration of nicotine-induced sensitization of
EGFR in benign and malignant breast cancer cells.
Intriguingly, we found that in nicotine-mediated
action, EGFR activation led to an increase of E2F1
activity, resulting in the promotion of DNA synthesis
and cell proliferation. In this process, EGFR appears as
a rate limiting factor and ERK1/2 functions as an
executor of the cell growth program. Previously, we
established that exposure to nicotine activates Raf and
PKC pathways in Rat or murine lung epithelial or can-
cer cells, which facilitate the genesis and development
of tumors [23-26]. EGFR has been shown to mediate
at least two pathways in cancer cells: the cytosolic and
the nuclear pathways. Emerging evidence indicates that
upon activation, some of EGFR or its family members
in cancer cells relocate to the nucleus, where they par-
ticipate in the regulation of gene transcription, cell
cycle checkpoints and DNA repair. It is still under
investigation whether EGFR upon nicotine treatment
in our experimental setting translocates to the nucleus
or is degraded. The present data suggest that upon
nicotine exposure, EGFR appears to play a significant
role in breast tumorigenesis.
Tobacco smoke or nicotine can reduce the efficacy of
chemo-treatments and increase cancer onset, develop-
ment or recurrence. Studies showed that in response to
nicotine exposure, cancer cells became resistant to cyto-
toxicity triggered by anti-cancer drugs. Bcl-2 was
reported to play an important role in nicotine-induced
anti-apoptotic or pro-survival activities [35,36]. It was
demonstrated that nicotine treatment significantly pro-
tected breast cancer cells against the cytotoxicity of dox-
orubicin [35,36]. Here, we determined that Bcl-2 is one
of the targets of nicotine exposure. Our study also
demonstrated that Akt was involved in the regulation of
Bcl-2 expression and responsible for the long-term sur-
vival of the breast cancer cells. Together, it seems that
nicotine, through activation of Src and Akt, promotes
anti-apoptotic or pro-survival activities in breast cancer
cells. Thus, Src and Akt pathways might be the intracel-
lular targets for improving the treatment efficacy of
breast cancer patients who are active or passive smokers
or nicotine users.
Conclusions
In summary, our findings suggest that Src and EGFR
play pivotal roles in regulating nicotine-treated breast
cancer cell proliferation and survival. The molecular
mechanisms of the activation of Src and EGFR in nico-
tine-mediated action involve ERK1/2/E2F1 and Akt/Bcl-
2 pathways. The cooperation of these pathways causes a
full magnitude of the promotion of cell growth and sur-
vival, which are attractive targets for developing better
treatments for breast cancer.
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